Results 211 to 220 of about 20,657 (229)
Some of the next articles are maybe not open access.
Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer
Oncogene, 2019Pancreatic cancer is a deadliest type of malignancy and lacks effective intervention. We here report a potential strategy for treatment of this malignancy by the combination of arsenic trioxide (ATO) and BET bromodomain inhibitor JQ1. These two agents synergistically modulate multistages of autophagy and thus induce apoptosis effectively in pancreatic ...
Congling, Xu +9 more
openaire +2 more sources
The BET inhibitor JQ1 suppresses tumor survival by ABCB5-mediated autophagy in uveal melanoma.
Cellular SignallingUveal melanoma (UM), the most common adult ocular tumor, is aggressive and resistant to treatment, posing threat to patients' lives. The novel, effective therapies and the exploration of chemosensitizer for UM are imperative.
Weiqin Liu +13 more
semanticscholar +1 more source
Effect of TNIK upregulation on JQ1-resistant human colorectal cancer HCT116 cells
Biochemical and Biophysical Research Communications, 2020JQ1 disrupts the binding of bromodomain and extra-terminal (BET) family of proteins to acetylated histones, modulates the expression of various genes, and inhibits the proliferation of cancer cells. We established two JQ1-resistant sublines from human colorectal cancer HCT116 cells. These resistant cells showed an 8- to 9-fold higher resistance to JQ1,
Chihiro Takahashi +6 more
openaire +2 more sources
Nano letters (Print), 2021
JQ1, a specific inhibitor of bromodomain-containing protein 4 (BRD4), could have great potential in the treatment of cervical cancer. However, its clinical application is limited by its short plasma half-life and limited antitumor efficacy. In this work,
Yinan Wang +7 more
semanticscholar +1 more source
JQ1, a specific inhibitor of bromodomain-containing protein 4 (BRD4), could have great potential in the treatment of cervical cancer. However, its clinical application is limited by its short plasma half-life and limited antitumor efficacy. In this work,
Yinan Wang +7 more
semanticscholar +1 more source
SOX9 is controlled by the BRD4 inhibitor JQ1 via multiple regulation mechanisms
Biochemical and Biophysical Research Communications, 2019SOX9 is a key transcription factor during cell differentiation, sex determination, and tumorigenesis. However, the detailed mechanisms of its targeting strategy remain elusive. To investigate possibilities of targeting SOX9 with epigenetic drugs and the precise underlying mechanisms, two human cancer cell lines were chosen as model systems, which ...
Seong Hwi Hong, Jueng Soo You
openaire +2 more sources
European Journal of Cancer, 2020
BACKGROUND Overexpression of c-Myc is commonly seen in human ovarian cancers, and this could be a potentially novel therapeutic target for this disease.
T. Bagratuni +13 more
semanticscholar +1 more source
BACKGROUND Overexpression of c-Myc is commonly seen in human ovarian cancers, and this could be a potentially novel therapeutic target for this disease.
T. Bagratuni +13 more
semanticscholar +1 more source
Upregulation of Mcl-1 inhibits JQ1-triggered anticancer activity in hepatocellular carcinoma cells
Biochemical and Biophysical Research Communications, 2018Bromodomains and extra-terminal (BET) proteins inhibitors are promising cancer therapeutic agents. However, tumor cells often develop resistance to BET inhibitors, greatly limiting their therapeutic potential. To study the mechanism underlying the resistance of BET inhibitors in hepatocellular carcinoma (HCC) cells, we herein investigated the impact of
Hua-Peng, Zhang +7 more
openaire +2 more sources
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Cancer Letters, 2017Bromodomain inhibitors (JQ1 and I-BET 762) are a new generation of selective, small molecule inhibitors that target BET (bromodomain and extra terminal) proteins. By impairing their ability to bind to acetylated lysines on histones, bromodomain inhibitors interfere with transcriptional initiation and elongation.
Ana S, Leal +5 more
openaire +2 more sources
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source